Abiraterone acetate treatment affects fatigue in men with mCRPC

According to a retrospective analysis of data from a randomized, double-blind, Phase III clinical trial, abiraterone acetate (Zytiga™) can significantly lower levels of fatigue in men with metastatic, castration-resistant prostate cancer (as well extending survival).

These data were presented today at the European Multidisciplinary Cancer Congress by Dr. Cora Sternberg and colleagues. They are based on a re-analysis of information collected as part of the original Phase III clinical trial that led to the approval of abiraterone acetate for treatment of men with mCRPC earlier this year.

Dr. Sternberg is quoted as stating that:

One of the most distressing issues these metastatic castration-resistant prostate cancer patients face during hormone treatment is extreme fatigue. Our results show that abiraterone acetate therapy has the potential to reduce cancer-related fatigue in this patient population, in addition to the previously demonstrated survival benefit.

Detailed results from this retrospective analysis were not provided in the media release issued by the conference organizers.

2 Responses

  1. Excellent news, if confirmed.

  2. Great potential — I’m still fighting fatigue 18 months after coming off a 27-month stint!

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: